How Has The Size And Value Of The Circulating Tumor Cells Market Changed During The 2026–2030 Period?
The circulating tumor cells market size has grown rapidly in recent years. It will grow from $13.27 billion in 2025 to $14.99 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to increasing cancer incidence rates, expansion of oncology research programs, growing use of blood-based diagnostics, rising adoption of minimally invasive testing methods, availability of advanced laboratory technologies.
The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $23.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of personalized oncology diagnostics, rising investments in cancer biomarker research, expansion of automated cell capture technologies, growing demand for early-stage cancer detection tools, increasing integration of ai in oncology diagnostics. Major trends in the forecast period include increasing use of liquid biopsy techniques, rising adoption of microfluidic ctc isolation devices, growing integration of automated ctc analysis systems, expansion of oncology research applications, enhanced focus on early cancer detection.
Claim Your Free Report Sample Today:
What Fundamental Drivers Are Expected To Boost The Circulating Tumor Cells Market Throughout The Forecast Period?
The growing incidence of cancer is expected to propel the circulating tumor cells market growth going forward. Cancer refers to a disease in which a few body cells grow uncontrollably and spread to other parts. Circulating tumor cells are used to help in the early detection and diagnosis of cancer, and thus growing incidence of cancer propels the growth of the circulating tumor cells market. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing incidence of cancer is driving the growth of the circulating tumor cells market.
What Are The Key Segmentation Components That Define The Structure Of The Circulating Tumor Cells Market?
The circulating tumor cells market covered in this report is segmented –
1) By Product: Kits And Reagents, Blood Collection Tubes, Devices Or Systems
2) By Technology: CTC Enrichment, CTC Detection, CTC Analysis
3) By Application: Clinical Or Liquid Biopsy, Research
Subsegments:
1) By Kits And Reagents: Cell Enrichment Kits, Detection Kits, Nucleic Acid Isolation Kits
2) By Blood Collection Tubes: Standard Blood Collection Tubes, Specialized Blood Collection Tubes
3) By Devices Or Systems: Microfluidic Devices, Automated Cell Capture Systems, Imaging Systems
What Trends Are Driving Change Across The Circulating Tumor Cells Market Landscape?
Major companies operating in the circulating tumor cells (CTC) market are focusing on developing innovative solutions, such as biomarker-specific CTC assays, to meet the rising demand for precise, non-invasive cancer diagnostics and advanced personalized therapy monitoring. Biomarker-specific CTC assays enable the detection and characterization of circulating tumor cells based on specific protein expression, offering more detailed phenotypic information than traditional CTC enumeration methods, which mainly provide total cell counts without biomarker differentiation. For instance, in July 2023, Menarini Silicon Biosystems S.p.A., an Italy-based diagnostics company, introduced the CELLSEARCH CTC test with the DLL3 biomarker, now available as a Research Use Only (RUO) service in North America and Europe. The assay leverages the FDA-cleared CELLSEARCH platform to detect circulating tumor cells expressing DLL3, a protein overexpressed in aggressive small-cell lung cancer (SCLC) and neuroendocrine tumors. By focusing on DLL3, the test enables phenotypic characterization of CTCs associated with poor prognosis, supporting biopharma research in developing targeted therapies. This innovation provides researchers with a non-invasive tool to study tumor heterogeneity, monitor disease progression, and evaluate response to targeted treatments.
Who Are The Standout Companies Known For Innovation In The Circulating Tumor Cells Market?
Major companies operating in the circulating tumor cells market are BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., ScreenCell SAS, Aviva Biosciences Corporation, LungLife AI Inc., Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd., Bio-Techne Corporation, Qiagen N.V., STEMCELL Technologies Inc., Sysmex Corporation, Miltenyi Biotec GmbH, Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Agilent Technologies Inc.
Get Your In-Depth Circulating Tumor Cells Market Report Now:
Which Regions Stand Out As Major Contributors To Future Demand In The Circulating Tumor Cells Market?
North America was the largest region in the circulating tumor cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment